Home > Healthcare > Pharmaceuticals > Finished Drug Form > Antidepressant Drugs Market

Antidepressant Drugs Market Analysis

Report ID: GMI2505
Published Date: Sep 2021
Report Format: PDF

Download Free Sample

Antidepressant Drugs Market Analysis

Serotonin-norepinephrine reuptake inhibitors (SNRIs) segment held around 9% of the antidepressant drugs market share in 2020. SNRIs are used as second line drug regime to treat patients suffering from anxiety and depression disorders. Its expanding applications in the treatment of abnormal psychological changes with better efficacy will enhance the product demand. Furthermore, these drugs are also proven to be effective for treatment of long-term nerve pain in anxiety disorders.

Antidepressant Drugs Market Size

To get key market trends

Download Free Sample

Generalized anxiety disorder (GAD) segment in the antidepressant drugs market is expected to showcase 7.8% growth rate through 2027. According to the Anxiety and Depression Association of America (ADAA), among 6.8 million people suffering from GAD, only 43.2% patients are receiving treatment in the U.S. Significant portion of population inclining towards overthinking about everyday life events contributes to rising patient pool.

Europe antidepressant drugs market accounted for more than 25% of revenue share in 2020 led by the growing awareness about therapies for mental disorders. Along with disease prevalence, rising disposable income, high healthcare spending, infrastructure development and availability of skilled workforce to address patient pool will foster the number of patients accessing treatment. Moreover, product launches to address concerns regarding various anxiety disorders by regional market participants expands drugs availability. Further, strong pipeline resulting into new product launches in future will spur revenue growth in the region.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market size of antidepressant drugs was over USD 13.5 billion during 2020 and is expected to witness around 7.2% CAGR up to 2027 with increased access to a large number of products.

Serotonin-norepinephrine reuptake inhibitors (SNRIs) class of drugs held nearly 9% of global antidepressant drugs industry share in 2020 and will grow due to increasing cases of depression and anxiety disorders.

The key types of antidepressant drugs include Serotonin-norepinephrine Reuptake Inhibitors (SNRIs), Selective Serotonin Reuptake Inhibitors {SSRIs} and Tricyclic Antidepressants.

Europe market held more than 25% of revenue share in 2020 and will expand with rising awareness and acceptance of mental disorders and related therapies.

Leading antidepressant drug manufacturers worldwide include Novartis, GlaxoSmithKline, Pfizer, Eli Lilly & Company, Janssen Pharmaceuticals, Bristol-Myers Squibb, Sandoz Inc., Otsuka Pharmaceutical and Sun Pharmaceuticals, among some others.